First- and second-line therapy of metastatic colorectal cancer

Keyphrases

• First-line Therapy 100%
• Second-line Therapy 100%
• Colorectal Cancer 100%
• Metastatic Colorectal Cancer (mCRC) 100%
• Standard of Care 50%
• Lung Cancer 50%
• Cancer Causes 50%
• Cancer Mortality 50%
• 5-fluorouracil (5-FU) 50%
• Overall Survival 50%
• Conventional Chemotherapy 50%
• Epidermal Growth Factor Receptor Inhibitors 50%
• Cetuximab 50%
• Disease Course 50%
• Combination Regimen 50%
• Colorectal Cancer Patients 50%
• Bevacizumab 50%
• Oxaliplatin 50%
• Cancer Cases 50%
• Prevalent Cancers 50%
• Advanced Colorectal Cancer 50%
• Irinotecan 50%
• Active Agent 50%
• Best Supportive Care 50%
• Biological Agents 50%
• Panitumumab 50%
• Vascular Endothelial Growth Factor Inhibitors 50%

Medicine and Dentistry

• Metastatic Colorectal Cancer 100%
• Colorectal Carcinoma 100%
• Diseases 66%
• Malignant Neoplasm 33%
• Lung Cancer 33%
• Cancer Mortality 33%
• Overall Survival 33%
• Biological Product 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Cetuximab 33%
• Bevacizumab 33%
• Oxaliplatin 33%
• Supportive Care 33%
• Irinotecan 33%
• Fluorouracil 33%
• Panitumumab 33%
• Vasculotropin Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Metastatic Colorectal Cancer 100%
• Colorectal Carcinoma 100%
• Diseases 66%
• Malignant Neoplasm 33%
• Biological Product 33%
• Cancer Mortality 33%
• Chemotherapy 33%
• Fluorouracil 33%
• Overall Survival 33%
• Epidermal Growth Factor Receptor Kinase Inhibitor 33%
• Cetuximab 33%
• Bevacizumab 33%
• Oxaliplatin 33%
• Lung Cancer 33%
• Irinotecan 33%
• Panitumumab 33%
• Vasculotropin Inhibitor 33%